Robinson Bradshaw

Topic: Complete Genomics

Next-Gen Sequencing Heading to Madison Avenue?

For companies seeking to make their mark in the ultra-competitive next-generation sequencing (NGS) market, new technology and lower prices may no longer be enough. As the size of the NGS sequencing market grows and an increasing number of NGS purchasers evaluate an expanding array of providers and technologies (see William Blair’s Next-Generation Sequencing Survey), NGS companies […]

A Googol of Genomes?

Earlier this week we took a look back at 2010 and offered our projections for the coming year in personal genomics. Topic #1, just as it was last year: the $1,000 genome. In hindsight, it might have been ill-advised to offer predictions about the near-term future of genome sequencing during the same week in which […]

2011 Personal Genomics Preview: It’s Déjà Vu…

Last January we kicked off the new year by posing “Five Questions for Personal Genomics in 2010.” Here were the five questions we asked: 1. Will the $1,000 genome live up to the hype? 2. Will personal genomics stay DTC? 3. How will the ongoing gene patent debate affect the progress of personalized medicine? 4. […]

Next-Gen Sequencing Update: Sequencing for Thousands, Suing for Millions

It is shaping up to be an eventful fourth quarter for genomic sequencing companies. Investors welcomed sequencing newcomer Pacific Biosciences (PacBio) to the public stage with a strong initial public offering (IPO). According to The Wall Street Journal, the company managed “the first U.S. life-sciences [IPO] this year to price well and trade higher” (although […]

Life Technologies Fires Latest Sequencing Salvo

Another week, another drop in the cost of whole-genome sequencing. The latest announcement comes from Life Technologies, which yesterday announced the launch of its SOLiD 4 sequencing system. The details of the announcement are well-covered by GenomeWeb and Matthew Herper of Forbes.com. In brief, the SOLiD 4 generates 100 gigabases of data per run at […]

GLR Update: In The Battle for Sequencing Supremacy, is 128 > $10,000?

The biggest industry developments last week were being announced at J.P. Morgan’s 28th Annual Healthcare Conference in San Francisco. The Genomics Law Report covered Illumina’s announcement of its new next-generation genomic sequencing machine (Another Stop on the Road to the $1,000 Genome), the HiSeq 2000, which promises to sequence an entire genome in one week […]

Another Stop on the Road to the $1,000 Genome

The latest stop on the road to the $1,000 genome? San Francisco, CA, where J.P. Morgan’s 28th Annual Healthcare Conference is in full swing. There is an abundance of real-time Twitter coverage from the conference, but certain announcements warrant a more detailed discussion. The announcement generating the biggest buzz today came from Illumina, Inc., whose […]

Five Questions for Personal Genomics in 2010

Death, taxes and January prediction columns: these things are inevitable. So what? A new year offers a convenient—if arbitrary—time to review the year that was and contemplate what lies ahead. Without further ado, here are five of the questions the Genomics Law Report is asking as we kick off 2010. 1. Will the $1,000 genome […]

Completing the Personal Genomics Toolkit

The big news buzzing through the world of genomics this afternoon is the publication of a paper in the journal Science announcing the production of three whole-genome sequences at an average materials cost of $4,400. The work was performed by the third-generation sequencing company Complete Genomics Incorporated, along with researchers from George Church’s lab at Harvard […]

Make Room for Big Blue: IBM the Latest (and Largest) Entrant in the Race for the $1,000 Genome

The quest for the $1,000 genome—viewed by many as the point at which whole-genome sequencing will become cost-effective and widely available—is a fierce competition populated by a cast of start-ups and specialized genomics companies. The most well-known entrants in the next-generation sequencing market are companies such as Oxford Nanopore, Pacific Biosciences and Complete Genomics; names that […]